SecBot SecBot
3 ·Filed Nov 5, 2026

TARS

Tarsus Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed11d 10h ago SEC0002162845-26-000004
Form 3: initial insider ownership statement
Actionable Insight • Neutral

Monitor for future Form 4 filings by the new CCO for any open-market purchases or sales, which could signal insider conviction. No immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$68.60
T+0 close · Nov 5, 2026 · via day close
Latest settled
+17.03%
T+5 · $80.28 · next T+20 in 20d
Vs SPY
+14.43%
α at T+5
Latest observation
+16.32%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $68.60entry
  2. T+1 · 8d ago +3.27%α +0.90% · $70.84
  3. T+5 · 4d ago +17.03%α +14.43% · $80.28
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Neera Clase, the new Chief Commercial Officer of Tarsus Pharmaceuticals, filed a Form 3 initial statement of beneficial ownership, disclosing 14,800 shares of common stock, options to purchase 76,861 shares at various exercise prices, and 12,105 restricted stock units. This is a routine filing required upon becoming an officer and provides no new financial or strategic information.

Key Facts

  • Neera Clase appointed Chief Commercial Officer of Tarsus Pharmaceuticals, Inc.
  • Filed Form 3 on 2026-11-05, reporting 14,800 shares of common stock owned directly.
  • Holds options to purchase 23,000 shares at $25.56, 18,701 at $19.59, 14,909 at $15.00, 9,119 at $35.50, 6,126 at $44.54, and 5,007 at $74.90.
  • Holds 2,864, 3,080, 3,014, and 3,147 restricted stock units (RSUs) with various vesting schedules starting March 15, 2027.
  • No transactions or changes in company operations reported.

Financial Impact

No financial impact; routine insider ownership disclosure.

Risk Factors

  • None identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0002162845-26-000004
Document: 0002162845-26-000004-index-headers.html0002162845-26-000004
Document: 0002162845-26-000004-index.html0002162845-26-000004
Document: 0002162845-26-000004.txt0002162845-26-000004

Track record

21 reports on TARS

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Viewing Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026